Beijing Centergate Technologies Holding Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.72, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.18, suggesting limited short-term liquidity cushion. The price-to-book ratio of 2.05 and price-to-tangible-book ratio of 2.05 indicate that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio of 90.46 and enterprise value to revenue ratio of 6.53 suggest a high valuation relative to earnings and revenue.

Profitability metrics show a return on equity of 1.58% and a return on assets of 0.66%, both of which are below the typical thresholds for pharmaceutical companies, indicating weak returns relative to equity and asset base. The gross profit margin is 56.2%, and the operating margin is 7.2%, which are in line with the industry but suggest limited pricing power or cost control. The net profit margin is 3.7%, which is also in line with the industry but indicates a thin margin of profitability.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's revenue of 666.93 million CNY is derived from pharmaceutical products, with no material revenue from other sources.

The company's growth trajectory is modest, with no disclosed revenue growth in the most recent period. The price-to-earnings ratio of 130.19 suggests that the market is paying a high multiple for earnings, which may reflect expectations of future growth or a premium for the company's product portfolio. The company's capital expenditure of -51.52 million CNY indicates a reduction in investment in physical assets, which may signal a focus on cost control or a shift in strategic priorities.

The company's risk profile includes a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates a potential liquidity constraint. The company's debt level of 1.13 billion CNY and equity of 1.57 billion CNY suggest a balanced capital structure, but the negative net cash position may require careful management of working capital and debt servicing. No material dilution events are currently expected, and the company's shares outstanding have not changed in the recent period.

Recent events include the disclosure of financial results showing a net income of 24.76 million CNY and an operating income of 48.18 million CNY. The company's market price of 4.28 CNY and market cap of 3.22 billion CNY reflect investor sentiment and valuation expectations. No recent filings or transcripts have been disclosed that would materially affect the company's operations or financial position.

Beijing Centergate Technologies Holding Co Ltd (000931.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals. This taxonomic update provides a clearer definition of the company’s operational focus, establishing a baseline for sector-specific analysis. Concurrently, the company’s risk profile has been initialized with specific assessments. Dilution risk is currently rated as low, suggesting limited immediate pressure from share issuance or similar capital structure changes. Liquidity risk, however, is assessed at a medium level. This indicates potential constraints or volatility in trading volume or market depth that investors should monitor, contrasting with the more stable dilution outlook. The firm currently operates with a minimal public footprint in terms of analyst coverage and index inclusion, with zero analysts tracking the stock and no index memberships recorded. Additionally, there are no reported top holders, and the officer count stands at one, reflecting a lean or opaque corporate structure in available data.

Cash conversion ratio of 2.03 ranks in the top quartile, significantly outperforming the cohort median of 0.95.

Revenue grew at a 5.7% compound annual rate over four years, demonstrating consistent top-line expansion despite recent volatility.

The company generated positive free cash flow of 87.9 million CNY in 2009, maintaining liquidity despite declining trends.

Dilution risk is assessed as low, suggesting minimal threat to existing shareholder equity value from share issuance.

Debt-to-equity ratio of 0.72 places the company in the bottom quartile, signaling significantly higher leverage than peers.

Credit risk is flagged as high, indicating substantial potential for financial distress or default compared to industry norms.

Revenue ¥622.5M, −6,7% YoY; Operating income −16,7% YoY.

• ▍Revenue ¥622.5M, −6,7% YoY
• ▍Operating income −16,7% YoY
• ▍Net income −6,9% YoY
• ▍Net margin 3.7%

Revenue ¥643.6M, −2,0% YoY; Operating income −36,0% YoY.

• ▍Revenue ¥643.6M, −2,0% YoY
• ▍Operating income −36,0% YoY
• ▍Net income −29,9% YoY
• ▍Net margin 1.7%

Revenue ¥656.5M; Operating income ¥33.4M.

• ▍Revenue ¥656.5M
• ▍Operating income ¥33.4M
• ▍Net margin 2.3%

Revenue ¥602.3M; Operating income ¥12.8M.

• ▍Revenue ¥602.3M
• ▍Operating income ¥12.8M
• ▍Net margin 0.3%

Revenue ¥616.3M; Operating income ¥23.3M.

• ▍Revenue ¥616.3M
• ▍Operating income ¥23.3M
• ▍Net margin 2.6%

Revenue ¥666.9M; Operating income ¥48.2M.

• ▍Revenue ¥666.9M
• ▍Operating income ¥48.2M
• ▍Net margin 3.7%

Revenue ¥2.44B, −3,5% YoY; Operating income −11,9% YoY.

• ▍Revenue ¥2.44B, −3,5% YoY
• ▍Operating income −11,9% YoY
• ▍Net income −10,7% YoY
• ▍Free cash flow −46,0% YoY
• ▍Net margin 2.0%

Revenue ¥2.53B, +11,2% YoY; Operating income +51,2% YoY.

• ▍Revenue ¥2.53B, +11,2% YoY
• ▍Operating income +51,2% YoY
• ▍Net income +9,9% YoY
• ▍Free cash flow +16,8% YoY
• ▍Net margin 2.1%

Revenue ¥2.28B, +10,5% YoY; Operating income +908,2% YoY.

• ▍Revenue ¥2.28B, +10,5% YoY
• ▍Operating income +908,2% YoY
• ▍Net income +223,2% YoY
• ▍Free cash flow +1 891,7% YoY
• ▍Net margin 2.1%

Revenue ¥2.06B, +5,3% YoY; Operating income +87,0% YoY.

• ▍Revenue ¥2.06B, +5,3% YoY
• ▍Operating income +87,0% YoY
• ▍Net income +65,3% YoY
• ▍Free cash flow +108,6% YoY
• ▍Net margin -1.9%

Revenue ¥1.96B; Operating income -¥76.4M.

• ▍Revenue ¥1.96B
• ▍Operating income -¥76.4M
• ▍Net margin -5.8%